NDAORALTABLET
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUTOPAR (ritodrine hydrochloride) is an oral beta-2 adrenergic agonist indicated for premature labor management. It works by stimulating beta-2 receptors on uterine smooth muscle to inhibit contractions and delay delivery.
LOE Approaching
As a legacy product approaching LOE with moderate competitive pressure (30), the brand team is likely focused on defending market share and managing transition; expect smaller, efficiency-driven commercial operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked open positions and an LOE-approaching lifecycle, YUTOPAR career opportunities are limited and heavily weighted toward managed care defense and legacy brand stewardship. This is a consolidation/maintenance role, not a growth platform, suitable for professionals seeking stable, lower-pressure environments or those managing portfolio transitions at AstraZeneca.
Brand Manager
Worked on YUTOPAR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.